Skip to main content

Table 1 Clinico-pathologic characteristics of the 486 patients with HG-SOC

From: Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets

Vital status at last follow-up (No. of patients)
deceased living unknown
262 (54%) 217 (44%) 7 (2%)
years to death (years)
min median max
0.02 2.43 12.67
Years to last follow-up (years)
min median max
0.02 2.44 15.01
Years to tumor recurrence (years)
min median max
0.01 1.23 9.25
Age at diagnosis
min median max
27 59 89
Site of tumor first recurrence (No. of patients)
loco-regional metastasis unknown
124 (26%) 118 (24%) 244 (50%)
Stages (No. of patients)
1 2 3 4 unknown
14 (3%) 21 (4 %) 366 (75%) 72 (15%) 13(3%)
Grade (No. of patients)
1 2 3 4 unknown
4(1%) 57 (12%) 410 (84%) 1 (0%) 14 (3%)
Tumor residual disease (No. of patients)
1-10 mm 11-20 mm >20 mm no macroscopic disease unknown
212 (44%) 26 (5%) 79 (16%) 95 (20%) 74 (15%)
Primary therapy outcome (No. of patients)
complete response partial response progressive disease stable disease unknown
270 (56%) 56 (12%) 36 (7%) 23 (5%) 101 (21%)